These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 4074429)

  • 1. General pharmacological properties of cilostazol, a new antithrombotic drug. Part I: Effects on the central nervous system.
    Shintani S; Toba Y; Suzuki S; Ninomiya S; Umezato M; Hiyama T
    Arzneimittelforschung; 1985; 35(7A):1157-62. PubMed ID: 4074429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs.
    Shintani S; Watanabe K; Kawamura K; Mori T; Tani T; Toba Y; Sasabe H; Nakagiri N; Hongoh O; Fujita S
    Arzneimittelforschung; 1985; 35(7A):1163-72. PubMed ID: 3000392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of suloctidil on the central and peripheral nervous systems].
    Nishi H; Watanabe T; Mori M
    Nihon Yakurigaku Zasshi; 1983 Sep; 82(3):191-212. PubMed ID: 6319248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacology of beraprost sodium. 1st communication: effect on the central nervous system.
    Murata T; Sakaya S; Hoshino T; Umetsu T; Hirano T; Nishio S
    Arzneimittelforschung; 1989 Aug; 39(8):860-6. PubMed ID: 2510742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cilostazol on platelet aggregation and experimental thrombosis.
    Kimura Y; Tani T; Kanbe T; Watanabe K
    Arzneimittelforschung; 1985; 35(7A):1144-9. PubMed ID: 4074426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological studies with the alpha 2-adrenoceptor antagonist midaglizole. Part II: Central and peripheral nervous systems.
    Hirohashi M; Takasuna K; Kasai Y; Usui C; Kojima H
    Arzneimittelforschung; 1991 Jan; 41(1):19-24. PubMed ID: 1675569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
    Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
    Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
    Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
    Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on central nervous and sensory systems and other functions.
    Yamamoto S; Takemori E; Hasegawa Y; Nakao K; Inukai T; Nomura M; Morino K; Tsuchiyama M; Hasegawa K; Ikeda H
    Arzneimittelforschung; 1991 Jun; 41(6):602-7. PubMed ID: 1930347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation.
    Kawamura K; Watanabe K; Kimura Y
    Arzneimittelforschung; 1985; 35(7A):1149-54. PubMed ID: 4074427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological properties of procaterol, a newly synthetized, specific beta 2-adrenoceptor stimulant. Part I. Effects on the CNS (author's transl)].
    Hashimoto K; Shintani S; Yamashita S; Tei S; Takai M; Tsutsui M; Kawamura K; Ohkawa T; Hiyama T; Yabuuchi Y
    Nihon Yakurigaku Zasshi; 1979 Apr; 75(3):271-89. PubMed ID: 43821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system.
    Arisawa H; Imai E; Fujise N; Fukui K; Masunaga H
    Arzneimittelforschung; 2002; 52(1):14-20. PubMed ID: 11838269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
    Matsuno Y; Hori H; Oka M; Nakamura H; Ito T; Kadokawa T
    Arzneimittelforschung; 1986; 36(1):62-8. PubMed ID: 3513778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of azelastine hydrochloride, a novel anti-allergic drug, on the central nervous system.
    Kaneko T; Kitahara A; Ozaki S; Takizawa K; Yamatsu K
    Arzneimittelforschung; 1981; 31(8):1206-12. PubMed ID: 6117290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacological studies of 4-ethoxy-2-methyl-5-morpholino-3(2H)-pyridazinone (M73101). (5) Action of M73101 on the central nervous system (author's transl)].
    Sato M
    Nihon Yakurigaku Zasshi; 1979 Oct; 75(7):695-706. PubMed ID: 575516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of amezinium, a novel antihypotensive drug. VI. Effect on central nervous functions.
    Teschendorf HJ; Kretzschmar R; Kreiskott H; Weifenbach H
    Arzneimittelforschung; 1981; 31(9a):1580-8. PubMed ID: 7197973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.